A 52-year-old man from Mumbai with a 10-day history of fever and productive cough is admitted with community-acquired pneumonia. Sputum culture yields Staphylococcus aureus. The isolate is tested by the broth microdilution method, and the minimum inhibitory concentration (MIC) for oxacillin is 0.5 µg/mL. The CLSI breakpoint for oxacillin against S. aureus is: susceptible ≤2 µg/mL, resistant ≥4 µg/mL. What is the most appropriate interpretation and clinical action?

Explanation

## MIC Interpretation in Broth Microdilution Testing **Key Point:** The minimum inhibitory concentration (MIC) is the lowest antibiotic concentration that inhibits visible bacterial growth. MIC values are compared to CLSI breakpoints to determine susceptibility categories. ### CLSI Breakpoints for Oxacillin vs S. aureus | Category | MIC (µg/mL) | Clinical Interpretation | | --- | --- | --- | | Susceptible (S) | ≤2 | Organism will respond to standard dosing | | Resistant (R) | ≥4 | Organism will NOT respond; likely MRSA | | (No intermediate category for oxacillin vs S. aureus) | — | — | **Clinical Pearl:** An MIC of 0.5 µg/mL is well below the susceptible breakpoint of 2 µg/mL, indicating the isolate is **fully susceptible** to oxacillin. This is a methicillin-susceptible S. aureus (MSSA), not MRSA. Beta-lactams (oxacillin, nafcillin, flucloxacillin) are the drugs of choice for MSSA. **High-Yield:** - **MSSA (MIC ≤2):** Use beta-lactams (oxacillin, nafcillin, flucloxacillin) - **MRSA (MIC ≥4):** Use vancomycin, linezolid, daptomycin, or ceftaroline - **Borderline MRSA (MIC 1–2, but with heterogeneous resistance):** Rare; may require higher beta-lactam doses or alternative agents **Mnemonic:** **MIC ≤ 2 = MSSA = Beta-lactams OK** | **MIC ≥ 4 = MRSA = Avoid Beta-lactams** ### Why This Answer? The MIC of 0.5 µg/mL is ≤2 µg/mL (the susceptible breakpoint), so the isolate is oxacillin-susceptible MSSA. First-line therapy is oxacillin or nafcillin (beta-lactams), which are superior to vancomycin for MSSA in terms of bactericidal activity and clinical outcomes.